Sector
PharmaceuticalsOpen
₹1,495.5Prev. Close
₹1,498.9Turnover(Lac.)
₹11,667.18Day's High
₹1,520.1Day's Low
₹1,495.552 Week's High
₹1,67352 Week's Low
₹1,335Book Value
₹428.5Face Value
₹2Mkt Cap (₹ Cr.)
1,22,546.97P/E
23.57EPS
64.35Divi. Yield
1.0524 Sep 2025
12:00 AM
Board Meeting
Agenda : Audited Result
13 May 2025
12:00 AM
Dividend
Dividend Amount: 13
Record Date: 27 Jun, 2025
13 May 2025
12:00 AM
AGM
Announcement Date: 13 May, 2025
Tirzepatide acts on both GIP and GLP-1 receptors and is prescribed along with diet and exercise for adults with obesity, defined as a BMI of 30 or higher.
Here are some of the stocks that may see significant price movement: Bharti Airtel, Cipla, Gland Pharma, etc.
iCaltech, an ISO 13485-certified medical device company, is engaged in the design, development and commercialisation of diagnostic products with a strong focus on respiratory applications
At around 1.51 PM, Cipla was trading almost flat at ₹1,485.40 per piece, against the previous close of ₹1,485 on NSE.
At the end of the inspection, the US FDA issued a Form 483 with one observation which was received at the conclusion of the inspection during the closing meeting.
| Y/e 31 Mar( In .Cr) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 |
|---|---|---|---|---|
Equity Capital | 161.52 | 161.47 | 161.43 | 161.36 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 31,937.72 | 27,812.45 | 24,476.66 | 22,352.19 |
Net Worth | 32,099.24 | 27,973.92 | 24,638.09 | 22,513.55 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Revenue | 13,091.79 | 11,302.71 | 12,659.15 | 11,389.9 |
yoy growth (%) | 15.82 | -10.71 | 11.14 | 5.77 |
Raw materials | -5,090.24 | -4,103.61 | -4,319.21 | -4,155.49 |
As % of sales | 38.88 | 36.3 | 34.11 | 36.48 |
Employee costs | -1,729.16 | -1,703.58 | -1,911.08 | -1,785.94 |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Profit before tax | 3,546.23 | 2,784 | 2,964.31 | 1,988.92 |
Depreciation | -460.01 | -468.62 | -599.78 | -529.61 |
Tax paid | -856.84 | -739.35 | -646.14 | -442.88 |
Working capital | 1,746.54 | -61.34 | 1,238.17 | 865.57 |
Other operating items |
| Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 15.82 | -10.71 | 11.14 | 5.77 |
Op profit growth | 9.74 | 13.3 | 23.3 | 37.54 |
EBIT growth | 26.3 | -5.7 | 49.95 | 63.18 |
Net profit growth | 19.83 | 6.47 | 57.85 | 50.62 |
| Particulars (Rupees in Crores.) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|---|
Gross Sales | 27,145.4 | 25,446.63 | 22,473.18 | 21,623.36 | 18,988.52 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 27,145.4 | 25,446.63 | 22,473.18 | 21,623.36 | 18,988.52 |
Other Operating Income | 402.22 | 327.46 | 279.94 | 139.98 | 171.07 |
Other Income | 861.87 | 746.57 | 475.45 | 280.91 | 265.99 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,745.9 | 89.6 | 4,18,767.93 | 564.22 | 0.92 | 4,511.27 | 99.24 |
Divis Laboratories Ltd DIVISLAB | 6,380 | 67.38 | 1,69,384.88 | 696 | 0.47 | 2,660 | 578.26 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,759.5 | 59.62 | 1,27,236.23 | 597 | 0.16 | 2,707 | 249.83 |
Cipla Ltd CIPLA | 1,498.9 | 23.3 | 1,21,092.98 | 1,210.53 | 1.07 | 4,495.16 | 411.56 |
Dr Reddys Laboratories Ltd DRREDDY | 1,280 | 19.78 | 1,06,799.3 | 387.3 | 0.62 | 4,602.9 | 377.56 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman (Non-Executive)
Y K Hamied
Non Executive Director
Adil Zainulbhai
Managing Director & Global CEO
Umang Vohra
Company Sec. & Compli. Officer
Rajendra Chopra
Independent Director
Robert A Stewart
Independent Director
P R Ramesh
Independent Director
Mandar Purushottam Vaidya
Non Executive Director
Abhijit A Joshi
Non Executive Director
Kamil Hamied
Independent Director
Sharmila Paranjpe
Independent Director
Maya Hari
Independent Director
Dr Balram Bhargava
Cipla House Peninsula Buss Par,
Ganpatrao Kadam Mg Lower Parel,
Maharashtra - 400013
Tel: 91-22-24826000
Website: http://www.cipla.com
Email: cosecretary@cipla.com, contactus@cipla.com
Karvy Selenium Tow-B,
31&32 Financial Dist, Nanakramguda,
Hyderabad-500032
Tel: 91-40-67162222
Website: www.kfintech.com
Email: einward.ris@karvy.com
Summary
Cipla Ltd is one of India’s oldest and most trusted pharmaceutical companies, advancing affordable healthcare and developing a large global portfolio of medicines, APIs and complex therapies.
Company ...
Read More
Reports by Cipla Ltd
What is the Cipla Ltd share price today?
What is the Market Cap of Cipla Ltd?
What is the PE and PB ratio of Cipla Ltd?
What is the 52 Week High and Low of Cipla Ltd?
What is the CAGR of Cipla Ltd?
What is the shareholding pattern of Cipla Ltd?
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor), PFRDA Reg. No. PoP 20092018
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
